Biofrontera, Inc. Recognized for Rapid Sales Growth, Innovative Therapies and Marketing Excellence
09 juin 2022 09h44 HE
|
Biofrontera Inc.
Named Among the 10 Fastest-Growing Life Sciences Companies to Watch in 2022 by CIOCoverage Magazine New Ameluz® Marketing Campaign Receives Gold 2022 Award of Excellence from The Communicator...
Biofrontera AG announces initiation of clinical studies
16 nov. 2021 09h01 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that two...
Biofrontera AG: Ludwig Lutter appointed new Chief Financial Officer effective March 1, 2021
02 févr. 2021 10h35 HE
|
Biofrontera AG
Leverkusen, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical...
Biofrontera AG reports completion of the clinical phase of the pharmacokinetics study
08 oct. 2020 11h04 HE
|
Biofrontera AG
Leverkusen, Germany, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, reports the...
Biofrontera AG: German Federal Supreme Court overturns ruling of the Cologne Higher Regional Court
22 sept. 2020 12h02 HE
|
Biofrontera AG
Leverkusen, Germany, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that in...
Biofrontera AG signs non-binding term sheet for licensing agreement for Ameluz® in Poland with medac GmbH Sp. z o.o.
13 mars 2020 08h00 HE
|
Biofrontera AG
Leverkusen, Germany, March 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) today signed a non-binding term sheet for an exclusive license agreement with...
Biofrontera Announces Conference Call on November 19, 2019 to Discuss Third Quarter 2019 Financial Results
06 nov. 2019 05h30 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Biofrontera Receives Award at Fall Clinical Dermatology Conference 2019
23 oct. 2019 02h00 HE
|
Biofrontera AG
Leverkusen, Germany, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, was presented with...
Biofrontera shows robust growth during first six months of 2019
27 août 2019 02h15 HE
|
Biofrontera AG
Leverkusen, Germany, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera starts patient recruitment for U.S. Phase III Trial Evaluating Ameluz® / BF-RhodoLED® for Superficial Basal Cell Carcinoma
26 sept. 2018 03h15 HE
|
Biofrontera AG
Enrollment of 186 patients at 12 study sites in the U.S. startedPhase III trial completion for photodynamic therapy of superficial basal cell carcinoma expected in first half of 2020Filing for...